BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? (Q54407999)

29 May 2018

title

BRAF(V600E) mutation analysis in papillary thyroid carcinoma: is it useful for all patients? (English)

1 reference

29 May 2018

main subject

papillary thyroid cancer

1 reference

6

Akira Miyauchi

1 reference

29 May 2018

Yasuhiro Ito

1

1 reference

29 May 2018

Hiroshi Yoshida

2

1 reference

29 May 2018

Minoru Kihara

3

1 reference

29 May 2018

Kaoru Kobayashi

4

1 reference

29 May 2018

Akihiro Miya

5

1 reference

29 May 2018

publication date

1 March 2014

1 reference

29 May 2018

published in

World Journal of Surgery

1 reference

29 May 2018

volume

38

1 reference

29 May 2018

issue

3

1 reference

29 May 2018

page(s)

679-687

1 reference

29 May 2018

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

The prevalence and prognostic value of BRAF mutation in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF(V600E) mutation and the biology of papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF mutations in an Italian cohort of thyroid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-013-2223-2

Raf proteins and cancer: B-Raf is identified as a mutational target

21 January 2018

1 reference

12 December 2020

Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma

1 reference

12 December 2020

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia

1 reference

12 December 2020

The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane

1 reference

12 December 2020

Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?

1 reference

12 December 2020

The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas

1 reference

12 December 2020

Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.

1 reference

12 December 2020

Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population

1 reference

12 December 2020

Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status

1 reference

12 December 2020

A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period

1 reference

12 December 2020

Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989.

1 reference

12 December 2020

The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study

1 reference

12 December 2020

An expanded view of risk-group definition in differentiated thyroid carcinoma

1 reference

12 December 2020

BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism

1 reference

12 December 2020

Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival

1 reference

12 December 2020

Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up

1 reference

12 December 2020

10.1007/S00268-013-2223-2

Identifiers

DOI

1 reference

29 May 2018

1 reference

29 May 2018